Measurement of Smoking-Induced Neutrophil Activation

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Neutrophil involvement in the development of COPD by smokers is well recognised. However not all smokers develop overt lung disease. We have previously shown that uptake of FDG is related to neutrophil activity and can be measured by PET and that uptake is greater in COPD patients than normal subjects. We have also shown that FDG-PET shows inflammatory changes in asymptomatic smokers after cigarette smoking. We plan to investigate the attenuation of this inflammation by steroid tablets and whether FDG PET can demonstrate this. We also wish to establish if similar changes are demonstrated after smoking by COPD patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College London
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Male smokers >10 pack.year history,

• FEV1>80% predicted,

• no relevant medical or mental disorder, able to give informed consent and

• Patients with COPD,

• >20 pack.year history,

• no other active lung disease,

• FEV1<70%

• FEV1/VC<70%,

• no other relevant medical or mental disorder, able to give informed consent

Exclusion Criteria:

• Female asymptomatic smokers

• ex-smokers

• other lung disorder

• relevant medical or mental illness

• recent (within 1 month) chest infection

• diabetes